SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer
SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer
Throughout his career, Mr. Honigblum has raised over half a billion dollars for various ventures. Notably, Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for $620 million.Seasoned Healthcare Executive to Lead Strategic Growth Initiatives
資深醫療行業高管將領導戰略增長計劃
Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations.
鹽湖城，猶他州，2024年11月19日（全球新聞網絡） -- sintx technologies, inc.（納斯達克：sint）（"sintx"或"公司"）是一家開發和商業化材料、元件以及用於醫療和技術應用的先進陶瓷公司，欣然宣佈Gregg R. Honigblum被任命爲首席策略官（CSO）。在這一職務中，Honigblum先生將負責推動公司的戰略，以支持sintx的增長計劃並增強投資者關係。
Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare sector. His career began on Wall Street as a stockbroker, transitioning into investment banking roles at various firms in New York City. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms with offices in New York and Austin, Texas, focusing on founding and funding breakthrough healthcare technologies.
Honigblum先生在醫療板塊的新興增長公司的高管角色中擁有超過35年的經驗。他的職業生涯始於華爾街作爲股票經紀人，隨後轉入紐約市各大公司的投資銀行業務。他共同創立了Creation Capital LLC和Creation Capital Advisors，這是一家在紐約和德克薩斯州奧斯丁設有辦公室，專注於創建和資助突破性醫療技術的投資銀行公司。
Throughout his career, Mr. Honigblum has raised over half a billion dollars for various ventures. Notably, Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for $620 million.
在他的職業生涯中，Honigblum先生爲各種風險籌集了超過五十億美元的資金。值得注意的是，Honigblum先生在爲萬基遺傳提供早期資本方面發揮了重要作用，萬基遺傳是第一家被認可的精準醫學診斷公司，因發現BRCA1和BRCA2乳腺癌基因而受到讚譽。此外，他還是Acacia Biosciences的早期投資者和融資者，這是一家早期信息基因組公司，與Rosetta Inpharmatics合併，隨後以62000萬被默沙東收購。
"Gregg's appointment as Chief Strategy Officer reflects our confidence in his ability to elevate SINTX's financial and strategic position," said Eric K. Olson, CEO of SINTX Technologies. "His successful career in emerging technologies and deep investment banking knowledge will be invaluable as we pursue new development opportunities, strengthen investor relationships, and drive our corporate strategy and revenue forward."
「Gregg被任命爲首席策略官，反映了我們對他提升sintx財務和策略地位能力的信懇智能，」sintx technologies的CEO Erik k. Olson說。「他在新興技術領域的成功職業生涯和深厚的投資銀行知識將對我們追求新的發展機會、加強投資者關係以及推動公司策略和營業收入前進大有裨益。」
Mr. Honigblum's deep understanding of the Company's mission and strategic goals, coupled with his experience as a former member of the board of Amedica, the predecessor of SINTX, positions him to drive the Company's corporate strategy effectively.
霍尼格布魯姆先生對公司使命和戰略目標的深刻理解，加上他作爲sintx的前身阿梅迪卡董事會成員的經驗，使他能夠有效地推動公司的企業策略。
"I am honored to join SINTX at this pivotal juncture," said Gregg R. Honigblum, Chief Strategy Officer. "The Company's ongoing development of pioneering technologies in the medical device sector positions it at the forefront of commercialization. I look forward to contributing to the team's efforts in enhancing shareholder value and drive the Company's vision forward."
「我很榮幸在這個關鍵時刻加入sintx，」首席策略官Gregg R. Honigblum說。「公司在器械板塊不斷開發開創性技術，使其處於商業化的前沿。我期待爲團隊增強股東價值和推動公司願景的努力做出貢獻。」
For more information, please visit
想獲取更多信息，請訪問
About SINTX Technologies, Inc.
關於SINTX Technologies, Inc。
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit .
sintx technologies是一家愛文思控股陶瓷公司，致力於爲醫療和技術應用開發和商業化材料、元件和技術。sintx是硅氮化物研究、開發和製造的全球領導者，其產品自2008年以來就被植入人體。在過去幾年裏，sintx利用戰略收購和聯盟進入新市場。公司在猶他州和馬里蘭州設有製造和研發設施。要了解更多關於sintx technologies或其材料平台的信息，請訪問。
Forward-Looking Statements
前瞻性聲明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.
本新聞發佈包含根據1995年《私人證券訴訟改革法案》（Private Securities Litigation Reform Act of 1995，簡稱PSLRA）作出的前瞻性陳述，這些陳述存在一定風險和不確定性。前瞻性陳述可通過詞語如："預測"，"相信"，"計劃"，"估計"，"期望"，"策略"，"未來"，"可能"，"應該"，"將來"等詞來識別。前瞻性陳述示例包括，我們關於陶瓷技術的進展和探索新的增長和創新途徑以及追求增長機會和探索戰略機會的能力。
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
請注意，讀者不應過分依賴前瞻性陳述，因爲它們僅爲管理層的當前估計、預測、期望和信念，準確反映管理層所了解的情況。由於前瞻性陳述涉及未來，它們受到難以預測且很多不可控因素導致的內在不確定性、風險和環境變化的影響。我們實際的結果和財務狀況可能與前瞻性陳述中所示的有所不同。可能導致我們實際結果和財務狀況與前瞻性陳述中所示不同的重要因素包括商業化陶瓷技術的困難和新產品機會的開發。關於其他可能導致我們實際結果和財務狀況與前瞻性陳述所示不同的風險和不確定因素，請參閱SINTX於2024年3月27日提交給SEC的公司年度報告（Form 10-k）中的風險因素披露，以及SINTX向SEC提交的其他申報文件。SINTX沒有義務公開修訂或更新前瞻性陳述，以反映本報告日期後出現的事件或情況，除非法律要求。
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
SINTX的業務和媒體諮詢：
SINTX Technologies
801.839.3502
IR@sintx.com
譯文內容由第三人軟體翻譯。
